Drugs of abuse are chemically divergent with distinct primary targets of action. Repeated intake of any drug of abuse, however, results in many common features of drug dependence. Activation of the mesocorticolimbic dopamine system has been implicated in the positive reinforcing (reward) effects of drugs of abuse, [1] [2] [3] [4] although recent studies demonstrated a dopamine-independent rewarding effect of morphine. 5, 6) The mesocorticolimbic dopamine reward system originates in the midbrain ventral tegmental area (VTA) and projects to the nucleus accumbens (NAc), prefrontal cortex and other limbic areas. The VTA-NAc dopamine system also plays a role in the discriminative stimulus effects of drugs. 7, 8) Once drug dependence has developed, it can be a life-long condition under which individuals show compulsive drug taking, intense cravings, and vulnerability to relapse even after years of abstinence. This is a major clinical problem in treating patients suffering from drug dependence. Basic and clinical studies suggest that aberrant synaptic plasticity in the prefrontal glutamatergic system innervating the NAc is related to compulsive drug seeking. 9) Brain imaging studies in addicted subjects revealed that craving is associated with the activation of the prefrontal cortex.
INTRODUCTION
Drugs of abuse are chemically divergent with distinct primary targets of action. Repeated intake of any drug of abuse, however, results in many common features of drug dependence. Activation of the mesocorticolimbic dopamine system has been implicated in the positive reinforcing (reward) effects of drugs of abuse, [1] [2] [3] [4] although recent studies demonstrated a dopamine-independent rewarding effect of morphine. 5, 6) The mesocorticolimbic dopamine reward system originates in the midbrain ventral tegmental area (VTA) and projects to the nucleus accumbens (NAc), prefrontal cortex and other limbic areas. The VTA-NAc dopamine system also plays a role in the discriminative stimulus effects of drugs. 7, 8) Once drug dependence has developed, it can be a life-long condition under which individuals show compulsive drug taking, intense cravings, and vulnerability to relapse even after years of abstinence. This is a major clinical problem in treating patients suffering from drug dependence. Basic and clinical studies suggest that aberrant synaptic plasticity in the prefrontal glutamatergic system innervating the NAc is related to compulsive drug seeking. 9) Brain imaging studies in addicted subjects revealed that craving is associated with the activation of the prefrontal cortex. 9, 10) To study the molecular mechanism of relapse, an animal model for relapse of drugseeking behavior has been established in mice by using a reinstatement procedure involving the intravenous self-administration of drugs. 11, 12) Regarding the long-lasting abnormalities in drug dependence, repeated exposure to amphetamine (AMPH) in rats produces a long-lasting increase in the length of dendrites, and the number of branched spines, 13) and interferes with the ability of experience in a complex environment to increase dendritic arborization and spine density in the NAc and prefrontal cortex. 14) We have demonstrated that repeated methamphetamine (METH) treatment results in a long-lasting impairment of novelty-induced extracellular signal-regulated kinase 1/2 activation in the prefrontal cortex in mice. 15) These structural and functional abnormalities may contribute to long-term behavioral consequences of drug abuse including drug dependence, psychosis, and cognitive impairment. Changes in transcription factors may result in long-term changes in gene expression, thereby contributing to neuronal adaptations associated with drug dependence. 16) For instance, a prolonged induction of DFosB, which can activate transcription at AP-1 sites, is a common response to many classes of addictive drugs. [17] [18] [19] Chronic drug exposure induces the expression of various neurotrophins, cytokines, and proteinases in the brain, which plays a crucial role in the development and relapse of drug dependence. [20] [21] [22] These endogenous modulators of drug dependence are functionally classified into two groups, pro-addictive and anti-addictive factors. 20) The former, including basic fibroblast growth factor (bFGF), 23, 24) brain-derived neurotrophic factor (BDNF), 25) tissue plasminogen activator (tPA), 26, 27) matrix metalloproteinase (MMP)-2 and MMP-9, 28) act to potentiate the rewarding effects of drugs, while the latter such as tumor necrosis factor-a (TNF-a) 29) and glial cell line-derived neurotrophic factor (GDNF) 30, 31) reduce the reward ( Table 1 ). The pathophysiological role of pro-addictive and anti-addictive factors in drug dependence is briefly described in this review article.
bFGF This neurotrophic factor is known to promote the growth and survival of midbrain dopaminergic cells. 32, 33) Repeated administration of AMPH in rats leads to a sustained increase in bFGF immunoreactivity in astrocytes in both the VTA and substantia nigra pars compacta, but not the NAc. 23) Notably, the development of behavioral sensitization to AMPH was prevented when a neutralizing antibody to bFGF was infused into the VTA. Co-treatment with an NMDA receptor antagonist blocked both the development of behav-ioral sensitization and bFGF's induction. 24) These findings suggest that endogenous bFGF is a pro-addictive factor necessary for the development of behavioral sensitization to AMPH and that bFGF mediates the glutamatergic-dopaminergic interaction that initiates the long-term consequences of repeated drug use.
BDNF BDNF is a member of the neurotrophin family, along with nerve growth factor (NGF), neurotrophin-3 (NT-3) and NT-4/5, and enhances the survival and function of dopaminergic neurons. 34) Infusion of BDNF into the NAc in rats resulted in an enhanced response to cocaine (COCA) reward-related stimuli, which persisted for more than a month after the cessation of infusions. 35) On the other hand, locomotor sensitization to COCA was delayed in heterozygous BDNF mutant [BDNF-(ϩ/Ϫ)] mice compared with wildtype littermates. 35) These findings suggest BDNF to be a proaddictive factor for the development of COCA dependence. Furthermore, in a rat model of drug craving, BDNF, but not NGF, levels in the VTA, NAc and amygdala progressively increased after COCA, but not sucrose, withdrawal. The timedependent increase in BDNF levels may suggest a role for BDNF in the craving of COCA. 25) Also, opiate withdrawal symptoms are markedly reduced despite normal antinociceptive tolerance in mice with a conditional deletion of BDNF in the postnatal brain. 36) Furthermore, Narita et al. (2003) have reported that METH-induced dopamine release and dopamine-related behavior in rats were significantly suppressed by pretreatment with an intra-NAc injection of either anti-BDNF or anti-TrkB antibody. 37) In contrast to these results supporting a role for BDNF as a pro-addictive factor, BDNF may act as an anti-addictive factor for alcoholism in reducing the behavioral effects of ethanol, including consumption. 38) Thus, voluntary ethanol consumption, ethanol reward, and behavioral sensitization to ethanol are enhanced in BDNF-(ϩ/Ϫ) mice compared with wild-type mice. Importantly, acute systemic administration of ethanol and voluntary ethanol consumption led to increased levels of BDNF in the dorsal striatum in mice. 38) tPA/Plasmin tPA, a serine protease that catalyzes the conversion of plasminogen to plasmin, plays an important role in fibrinolysis. tPA is also abundantly expressed in the central nervous system, where it is stored in synaptic vesicles and released into the extracellular space by depolarization. [39] [40] [41] Accumulating evidence has demonstrated that tPA plays a role in numerous aspects of synaptic plasticity and remodeling, including neurite outgrowth and neuronal development, the late phase of long-term potentiation, and memory. [42] [43] [44] Moreover, recent studies suggest that tPA acts as a modulator of neurotransmission and synaptic plasticity by impacting on glutamatergic and dopaminergic pathways. [45] [46] [47] A single injection of morphine (MORP) in rats and mice induces tPA mRNA and protein expression in MAP2-positive neuronal cells in a naloxone-sensitive manner, which is associated with an increase in the enzyme activity in the NAc. 26) Not only MORP but also other drugs of abuse such as METH, nicotine (NICO) and ethanol increase tPA expression and activity in the NAc. 27, 48, 49) Furthermore, these drugs of abuse promote the release of tPA from postsynaptic neurons into the extracellular space in the NAc by stimulating dopamine D1 and D2 receptors. 48, 50) Notably, dopamine D1 receptor/protein kinase A (PKA) signaling plays a major role in the regulation of tPA release in the NAc. 50) Behavioral analyses with tPA-deficient [tPA-(Ϫ/Ϫ)] and plasminogen-deficient [plg-(Ϫ/Ϫ)] mice revealed that the tPA/plasmin system plays a crucial role in the rewarding effects of MORP, 26, 51, 52) METH, 27) and NICO. 48) Behavioral sensitization to MORP and METH induced by repeated administration is suppressed in tPA-(Ϫ/Ϫ) mice. 26, 27) Furthermore, seizures after ethanol withdrawal are suppressed in tPA-(Ϫ/Ϫ) mice, suggesting a role for tPA in the development of physical dependence on ethanol.
49) Accordingly, tPA is regarded as a pro-addictive factor for psychological and physical dependence.
An in vivo microdialysis-based study revealed that MORPand NICO-induced dopamine release in the NAc was markedly decreased in tPA-(Ϫ/Ϫ) mice, but the deficit was restored by prior microinjection of recombinant tPA or plasmin into the NAc. These findings suggest that the tPA/plasmin system has a role in regulating dopamine release evoked by MORP and NICO in the NAc. 26, 48) Of note, the tPA/plasmin system contributes to the depolarization-induced release of dopamine in the NAc. 46) As a target of the tPA/plasmin system in regulating dopamine release in the NAc, proteaseactivated receptor-1 (PAR1-1) has been identified. 48, 53) Regarding the METH-induced release of dopamine in the NAc, the expression of tPA in the NAc after repeated METH treatment is related to the development of sensitization in dopamine transporter (DAT)-mediated METH-induced dopamine release via plasmin. 54) MMP/TIMP MMPs constitute a family of enzymes with more than 20 members identified to date, which require Zn 2ϩ for their enzymatic activity. MMP activity is regulated by interaction with tissue inhibitors of MMP (TIMPs), and thus the MMP/TIMP system is involved in the modulation of functional and structural remodeling of the cellular architecture in the context of pathophysiology primarily through the cleavage of extracellular matrix proteins, bioavailability of growth factors and cytokines, and shedding of membrane receptors. 55, 56) Gelatinases (MMP-2 and MMP-9) are capable of cleaving collagen IV and V, laminin, and chondroitin sulfate proteoglycan, which are associated with cell adhesion. MMP-9 is required for hippocampal long-term potentiation and memory. 57) Repeated METH treatment in rodents induces behavioral sensitization, which is accompanied by an increase in MMP-2 and MMP-9 activity in the NeuN-positive neuronal Repeated METH treatment is also accompanied by an increase in TIMP-2 expression. Antisense TIMP-2 oligonucleotide (TIMP-AS) treatment enhances the behavioral sensitization to METH, which is accompanied by the potentiation of METH-induced dopamine release in the NAc. On the other hand, the inhibitor of MMP-2/-9 blocks METH-induced behavioral sensitization and reward, which is associated with a reduction of METH-increased dopamine release in the NAc. Furthermore, repeated METH treatment results in a decrease in dopamine D2 receptor signaling in the frontal cortex of wild-type mice, but not in MMP-2-(Ϫ/Ϫ) and MMP-9-(Ϫ/Ϫ) mice. These results suggest that the MMP/TIMP system is involved in METH-induced behavioral sensitization and reward, by regulating dopamine release and receptor signaling.
58)
TNF-a a TNF-a, an inflammatory cytokine produced by macrophages and circulating monocytes, affects brain function directly or indirectly through stimulation of vagal afferents. 59) METH induces TNF-a gene expression in the brain of C57BL/6 mice 60) and in human brain endothelial cells.
61)
Repeated METH treatment increases TNF-a mRNA and protein levels in neurons of the NAc through the activation of dopamine receptors. 29) Recombinant TNF-a inhibits METHinduced reward, discriminative stimulus effects, and dopaminergic neurotoxicity. Conversely, responses to METH are enhanced in TNF-a-deficient [TNF-(Ϫ/Ϫ)] mice. Furthermore, TNF-a attenuates DAT-mediated METH-induced dopamine release in the NAc, and potentiates striatal dopamine uptake into synaptosomes in vitro and in vivo. This neuroactive cytokine activates vesicular dopamine uptake by itself, and diminishes the METH-induced decrease in vesicular dopamine uptake. It is proposed that TNF-a plays a neuroprotective role in METH-induced drug dependence and neurotoxicity by activating plasmalemmal DAT as well as vesicular monoamine transporter-2 (VMAT-2), and inhibiting METH-induced dopamine release. 29) A recent study demonstrated that repeated MORP treatment increases TNF-a expression in the NAc and striatum, and TNF-(Ϫ/Ϫ) mice show enhanced MORP reward, indicating that TNF-a acts to reduce MORP reward. 62) Interestingly, TNF-a induces GDNF expression in cultured neurons in vitro, 63) suggesting an interaction between anti-addictive factors (see below).
GDNF GDNF enhances the survival and growth of dopaminergic neurons after injury in vivo. [64] [65] [66] This cytokine exerts biological activity via the Ret receptor tyrosine kinase and GDNF-family receptor-a (GFRa1). The Ret receptor is shared by all four members of the GDNF family of growth factors and the specificity for GDNF is conferred by GFRa1. GDNF activates Ret tyrosine kinase by first binding the cognate GFRa1. 67) Infusion of GDNF into the VTA blocks biochemical adaptations to chronic COCA treatment (induction of tyrosine hydroxylase, NR1 subunit of NMDA receptors, DFosB and PKA catalytic subunit), which is associated with the reduction of COCA reward. 30) Conversely, responses to COCA are enhanced in rats by intra-VTA infusion of anti-GDNF antibody and in GDNF-(ϩ/Ϫ) mice. Chronic COCA treatment has no effect on GFRa1 and Ret protein levels in the mesolimbic dopamine system, but significantly reduces phosphorylated Ret levels. These results suggest a feedback loop, whereby chronic COCA treatment decreases GDNF signaling in the VTA, which then increases the behavioral sensitivity to subsequent drug exposure. 30) In agreement with the findings described above, a recent study supports a role for GDNF in the VTA in countering the addictive effects of alcohol. Thus, microinjection of GDNF into the VTA significantly suppresses alcohol consumption. 22, 68) A putative anti-addiction drug Ibogaine increases GDNF mRNA and protein expression and activates GDNF signaling, which is associated with the desirable action of reducing alcohol consumption. 69) Furthermore, GDNF-(ϩ/Ϫ) mice show enhancement of MORP reward compared with wild-type littermates. 70 ) Accordingly, it is suggested that GDNF acts as an anti-addictive cytokine in COCA, alcohol, and MOPR dependence. 20, 22) We have investigated a role for GDNF in the development and relapse of METH dependence by using intravenous selfadministration and the reinstatement of drug-seeking behavior in GDNF-(ϩ/Ϫ) mice, respectively. 31) The results indicated that GDNF potentiates METH self-administration, enhances motivation to take METH, increases vulnerability to drug-primed reinstatement, and prolongs the cue-induced reinstatement of extinguished METH-seeking behavior. In contrast, there is no significant difference in novelty responses, METH-induced hyperlocomotion and sensitization, food-reinforced operant behavior and motivation, or reinstatement of food-seeking behavior between GDNF-(ϩ/Ϫ) and wild-type littermates. Our findings suggest that GDNF is a potent antiaddictive factor involved in the development and relapse of METH dependence. 31) CONCLUSION AND REMARKS As reviewed in this article, various cytokines and proteinases are produced in the brain on treatment with drugs of abuse, and act as either pro-addictive or anti-addictive factors. Pro-addictive factors potentiate the rewarding effects of drugs of abuse, and thereby act to facilitate the development of drug dependence. Anti-addictive factors reduce the drug reward, and thus act to prevent the development of drug dependence. A potent anti-addictive factor GDNF is involved in not only the development but also the relapse of drug dependence. There may be interactions within and between pro-addictive and anti-addictive factors. I propose that changes in the balance between pro-addictive and anti-addictive factors in the brain play a crucial role in the development and relapse of drug dependence. Regulation of these endoge-nous modulators could be useful for the treatment of drug dependence.
